Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
October 10, 2005
- NEW PRODUCTS
October 10, 2005
- Brand Names of GE Drugs Must Be Based on Their Generic Names: Korosho
October 10, 2005
- Sawai: Survey Indicates Sharp Increase in GE Drug Awareness
October 10, 2005
- Actos Poised for Sharp Growth in Wake of PROactive Study: Takeda
October 3, 2005
- R&D NEWS IN BRIEF
October 3, 2005
- Global Bioventure Forum
October 3, 2005
- Medical Fees Likely to Be Cut in Next Revision in 2006: Prof. Niki
October 3, 2005
- Mediceo HD, Mitsubishi Corp. Tie-up in Medical Services Business
October 3, 2005
- Prevention Is More Important in Ensuring Safe Use of Drugs: SJP Seminar
October 3, 2005
- Kyoso Mirai Group to Establish Administrative Work Center
October 3, 2005
- How to Prepare CTD Explained at Joho Kiko Seminar
October 3, 2005
- BUSINESS NEWS IN BRIEF
October 3, 2005
- SSP Aims to Quickly Recover Sales Lost Through Business Transfer
October 3, 2005
- NEW PRODUCTS
October 3, 2005
- OTC Drugs Less Potent in Japan Than in the West: Mr Hishikura of GSK
October 3, 2005
- OPINION
October 3, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 3, 2005
- Committee on Health Insurance to Discuss Revision of Medical Fee System
October 3, 2005
- SURVEY 3 articles
October 3, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…